UK markets closed

Newron Pharmaceuticals S.p.A. (0QOI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
1.3300+1.3300 (+405.31%)
At close: 03:56PM GMT
Currency in CHF

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.66
52-week change 3N/A
S&P500 52-week change 3-11.22%
52-week high 30.0000
52-week low 30.0000
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 517.84M
Implied shares outstanding 6N/A
Float 816.96M
% held by insiders 14.96%
% held by institutions 17.31%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 3
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Jun 2022

Profitability

Profit margin -244.45%
Operating margin (ttm)-184.46%

Management effectiveness

Return on assets (ttm)-16.36%
Return on equity (ttm)-839.80%

Income statement

Revenue (ttm)5.92M
Revenue per share (ttm)0.33
Quarterly revenue growth (yoy)6.00%
Gross profit (ttm)5.76M
EBITDA -10.96M
Net income avi to common (ttm)-14.47M
Diluted EPS (ttm)-0.8500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)28.36M
Total cash per share (mrq)1.59
Total debt (mrq)44.47M
Total debt/equity (mrq)N/A
Current ratio (mrq)8.84
Book value per share (mrq)-0.29

Cash flow statement

Operating cash flow (ttm)-8.32M
Levered free cash flow (ttm)-7.45M